Technical Analysis for GLYC - GlycoMimetics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 2.25 | -1.32% | -0.03 |
Earnings due: May 1
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lower Bollinger Band Walk | Weakness | -1.32% | |
| Wide Bands | Range Expansion | -1.32% | |
| Oversold Stochastic | Weakness | -1.32% | |
| Lower Bollinger Band Walk | Weakness | 4.65% | |
| Wide Bands | Range Expansion | 4.65% | |
| Below Lower BB | Weakness | 4.65% | |
| Down 3 Days in a Row | Weakness | 4.65% | |
| Lower Bollinger Band Touch | Weakness | 4.65% | |
| Oversold Stochastic | Weakness | 4.65% | |
| Lower Bollinger Band Walk | Weakness | -0.22% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 3 hours ago |
| Down 3% | about 3 hours ago |
| Down 2 % | about 3 hours ago |
| 2x Volume Pace | about 3 hours ago |
| 1.5x Volume Pace | about 3 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/01/2024
GlycoMimetics, Inc. Description
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases. Its lead product includes GMI-1070, a glycomimetic drug candidate that acts as a pan-selectin antagonist has completed Phase II clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The company is also developing GMI-1271, a specific E-selectin antagonist, which it plans to initiate a Phase I dose-escalation clinical trials in healthy volunteers to be used in combination with chemotherapy to treat acute myeloid leukemia and potentially other hematologic cancers. In addition, its drug candidates comprise GMI-1051 and other drug candidates for pseudomonas virulence factors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Gaithersburg, Maryland.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Disease Drug Discovery Acute Myeloid Leukemia Chemotherapy Clinical Trial Product Testing Pseudomonas Sickle Cell Disease Hematologic Cancers Nursing Research
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.5299 |
| 52 Week Low | 1.11 |
| Average Volume | 396,375 |
| 200-Day Moving Average | 2.07 |
| 50-Day Moving Average | 2.85 |
| 20-Day Moving Average | 2.71 |
| 10-Day Moving Average | 2.48 |
| Average True Range | 0.22 |
| RSI (14) | 37.50 |
| ADX | 23.53 |
| +DI | 10.97 |
| -DI | 25.21 |
| Chandelier Exit (Long, 3 ATRs) | 2.52 |
| Chandelier Exit (Short, 3 ATRs) | 2.80 |
| Upper Bollinger Bands | 3.28 |
| Lower Bollinger Band | 2.14 |
| Percent B (%b) | 0.12 |
| BandWidth | 42.13 |
| MACD Line | -0.16 |
| MACD Signal Line | -0.10 |
| MACD Histogram | -0.0613 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.63 | ||||
| Resistance 3 (R3) | 2.62 | 2.51 | 2.57 | ||
| Resistance 2 (R2) | 2.51 | 2.42 | 2.51 | 2.55 | |
| Resistance 1 (R1) | 2.39 | 2.36 | 2.45 | 2.40 | 2.53 |
| Pivot Point | 2.28 | 2.28 | 2.31 | 2.28 | 2.28 |
| Support 1 (S1) | 2.16 | 2.19 | 2.22 | 2.17 | 2.03 |
| Support 2 (S2) | 2.05 | 2.13 | 2.05 | 2.01 | |
| Support 3 (S3) | 1.93 | 2.05 | 1.99 | ||
| Support 4 (S4) | 1.94 |
